KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Other Accumulated Expenses (2016 - 2025)

Nektar Therapeutics (NKTR) has 16 years of Other Accumulated Expenses data on record, last reported at $12.1 million in Q3 2025.

  • For Q3 2025, Other Accumulated Expenses fell 32.55% year-over-year to $12.1 million; the TTM value through Sep 2025 reached $12.1 million, down 32.55%, while the annual FY2024 figure was $9.9 million, 1.96% down from the prior year.
  • Other Accumulated Expenses reached $12.1 million in Q3 2025 per NKTR's latest filing, up from $9.8 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $20.0 million in Q3 2021 and bottomed at $6.4 million in Q2 2024.
  • Average Other Accumulated Expenses over 5 years is $12.5 million, with a median of $12.1 million recorded in 2025.
  • Peak YoY movement for Other Accumulated Expenses: crashed 54.73% in 2022, then surged 157.86% in 2024.
  • A 5-year view of Other Accumulated Expenses shows it stood at $15.5 million in 2021, then crashed by 54.73% to $7.0 million in 2022, then soared by 44.48% to $10.1 million in 2023, then dropped by 1.96% to $9.9 million in 2024, then increased by 21.81% to $12.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Accumulated Expenses were $12.1 million in Q3 2025, $9.8 million in Q2 2025, and $11.8 million in Q1 2025.